Drug Profile
Research programme: TNF antagonists - Xencor
Alternative Names: TNF monoclonal antibodies - Xencor; Tumour necrosis factor antagonists - XencorLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Xencor
- Class Monoclonal antibodies; Proteins; Tumour necrosis factors
- Mechanism of Action RANK ligand inhibitors; Tumour necrosis factor alpha inhibitors; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Bone disorders
- Discontinued Inflammation
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bone-disorders in USA (Parenteral)
- 11 Apr 2014 A biosuperior anti-TNF, Xtend-TNF, monoclonal antibody is still in preclinical trials for Autoimmune disorders in USA (Xencor's pipeline)